Sound View Wealth Advisors Group LLC Purchases 498 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sound View Wealth Advisors Group LLC boosted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 13.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,092 shares of the biotechnology company’s stock after acquiring an additional 498 shares during the quarter. Sound View Wealth Advisors Group LLC’s holdings in Sarepta Therapeutics were worth $498,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Manchester Capital Management LLC raised its holdings in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its position in Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after buying an additional 156 shares during the last quarter. Sunbelt Securities Inc. raised its holdings in Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 232 shares in the last quarter. Huntington National Bank lifted its position in shares of Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after buying an additional 175 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. bought a new stake in shares of Sarepta Therapeutics during the 4th quarter worth about $36,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SRPT has been the topic of a number of recent analyst reports. Royal Bank of Canada cut their price objective on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a research note on Thursday, February 27th. Needham & Company LLC reissued a “buy” rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 27th. StockNews.com cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. HC Wainwright reiterated a “sell” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. Finally, Piper Sandler dropped their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. One analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $170.41.

Insider Activity at Sarepta Therapeutics

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now owns 22,840 shares of the company’s stock, valued at $2,851,345.60. The trade was a 31.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.70% of the stock is currently owned by insiders.

Sarepta Therapeutics Trading Down 2.4 %

Shares of SRPT stock opened at $103.03 on Monday. The firm has a fifty day moving average of $114.11 and a 200-day moving average of $121.27. The stock has a market cap of $10.00 billion, a price-to-earnings ratio of 82.42 and a beta of 0.79. Sarepta Therapeutics, Inc. has a 52-week low of $99.50 and a 52-week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.